{"name":"Gildasio Castello de Almeida Junior","slug":"gildasio-castello-de-almeida-junior","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tranilast, and Tissucol","genericName":"Tranilast, and Tissucol","slug":"tranilast-and-tissucol","indication":"Hypertrophic scars and keloid prevention/treatment","status":"phase_3"}]}],"pipeline":[{"name":"Tranilast, and Tissucol","genericName":"Tranilast, and Tissucol","slug":"tranilast-and-tissucol","phase":"phase_3","mechanism":"Tranilast inhibits fibroblast proliferation and collagen synthesis, while Tissucol is a fibrin sealant that promotes tissue adhesion and hemostasis.","indications":["Hypertrophic scars and keloid prevention/treatment","Post-surgical wound healing and hemostasis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}